Literature DB >> 23229580

Perioperative allogenic blood transfusions and the risk of endometrial cancer recurrence.

Stefano Uccella1, Fabio Ghezzi, Antonella Cromi, Giorgio Bogani, Giorgio Formenti, Nicoletta Donadello, Maurizio Serati, Pierfrancesco Bolis.   

Abstract

PURPOSE: To evaluate the effect of perioperative blood transfusions on the risk of recurrence of endometrial cancer.
METHODS: This study is a retrospective analysis of 358 consecutive patients, without a history of other tumors, who underwent surgery for endometrial cancer between January 2000 and April 2010.
RESULTS: Women who did not need any transfusion (N = 331) and patients who received allogenic blood donations (N = 27) were compared in terms of risk of cancer recurrence. The surgical standard procedure included peritoneal washing for cytologic examination, total hysterectomy + bilateral adnexectomy (N = 358), and pelvic lymphadenectomy (N = 227). The two groups were homogeneous in term of age, BMI, previous abdominal surgery, type of intervention, operative time, nodal count, and hospital stay. The median (range) estimated blood loss was higher in the transfusion group, 400 mL (100-2,000 mL), than in the non-transfusion group, 150 mL (10-1,000 mL). Median (range) follow-up was 67.5 months (6-132.4 months). Blood transfusions were associated with a higher relapse rate (P = 0.0021). At multivariate analysis, administration of packed red blood cells remained independently associated with recurrence (OR 4.64; CI 95 % 1.45-14.9), as well as myometrial invasion ≥50 % (OR 2.88; CI 95 % 1.18-7.07) and stage >1 (OR 4.24; CI 95 % 1.75-10.3).
CONCLUSIONS: The use of allogenic blood transfusions is associated with a higher risk of recurrence. We hypothesize that this could be due to a transitory perioperative immunodepression that promotes the spread of neoplastic cells.

Entities:  

Mesh:

Year:  2012        PMID: 23229580     DOI: 10.1007/s00404-012-2668-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.

Authors:  Edward J Tanner; Olga T Filippova; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Oliver Zivanovic; Mary Fischer; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2018-10-16       Impact factor: 5.482

2.  Are Allogeneic Blood Transfusions Associated With Decreased Survival After Surgery for Long-bone Metastatic Fractures?

Authors:  Stein J Janssen; Yvonne Braun; John E Ready; Kevin A Raskin; Marco L Ferrone; Francis J Hornicek; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2015-01-31       Impact factor: 4.176

3.  Improvement of Perioperative Outcomes in Major Gynecological and Gynecologic-Oncological Surgery with Hemostatic Gelatin-Thrombin Matrix.

Authors:  Rafał Watrowski; Christoph Jäger; Johannes Forster
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

4.  Impact of perioperative red blood cell transfusion, anemia of cancer and global health status on the prognosis of elderly patients with endometrial and ovarian cancer.

Authors:  Katharina Anic; Mona Wanda Schmidt; Marcus Schmidt; Slavomir Krajnak; Amelie Löwe; Valerie Catherine Linz; Roxana Schwab; Wolfgang Weikel; Walburgis Brenner; Christiane Westphalen; René Rissel; Erik Kristoffer Hartmann; Roland Conradi; Annette Hasenburg; Marco Johannes Battista
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

5.  Reoperation after oesophageal cancer surgery in relation to long-term survival: a population-based cohort study.

Authors:  Maartje van der Schaaf; Maryam Derogar; Asif Johar; Martin Rutegård; James Gossage; Robert Mason; Pernilla Lagergren; Jesper Lagergren
Journal:  BMJ Open       Date:  2014-03-20       Impact factor: 2.692

6. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-08       Impact factor: 1.595

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.